Drugs / GC012F Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06530849 | Aug 2024 → Feb 2027 expected | systemic lupus erythematosus | Gracell Biotechnologies (Shanghai) Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC012F Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06530849 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell therapy” NCT06530849 ↗ |
| Target | CD19 | “GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19” NCT06530849 ↗ |